Biobeat: Funding, Investors & Team (Oct 2026)

Biobeat develops a wearable device for continuous, noninvasive, accurate, medical-grade monitoring of vital signs that include blood pressure, oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat. Its wearable device automatically uploads the recorded data to a smartphone-based application and to the cloud, where the application can monitor it remotely. Caretakers can intervene if needed, and users can receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and optimize clinical outcomes. The Biobeat system also facilitates remote monitoring of patients with a variety of medical issues. Ultimately, this solution allows patients to be treated in their homes. It can monitor stationary patients as well as those who perform outdoor activities. In 2018, Biobeat received FDA 510K clearance (K181006) for its monitoring system and partnered with DRIVe, a division of the Biomedical Advanced Research and Development Authority, to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear. In August 2019, Biobeat received 510K FDA clearance for its patch and watch.

Biobeat has raised $50.0M across 1 round on record. The most recent is a Series B of $50.0M announced in Dec 2025.

Biobeat's most recent funding round on record is a Series B of $50.0M, announced in Dec 2025.

FundedIQ lists Arik Ben Ishay (Founder) at Biobeat.

Biobeat is based in Boca Raton, Florida, United States.

Biobeat is in the 11-50 employee band.

Biobeat's latest round of $50.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.